The clearest coverage concentration is pharma: 8 of 9 stories, with the rest divided among 1 other category. Against the same-window beat baseline of 16% negative, this entity's 44% share is more negative. GSK is the most frequent co-covered peer, appearing in 4 of the 9 tracked stories.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about CDC
The clearest coverage concentration is pharma: 8 of 9 stories, with the rest divided among 1 other category. Against the same-window beat baseline of 16% negative, this entity's 44% share is more negative. GSK is the most frequent co-covered peer, appearing in 4 of the 9 tracked stories. Across a 116-day span, the pace is roughly 0.5 stories per week. The busiest single day carried 2. Their average consequence score of 6.4 runs above the beat's 6.1 for that window. They are less corroborated than the beat average, carrying 2.8 original sources each against 3.4 for the same window. This profile follows 9 Biotech stories mentioning CDC across the period from February 20, 2026 to June 15, 2026.
Stories tracked
9
Per week
0.5
Negative
44%
Sources per story
2.8
Computed from the 9 stories linked to this entity, with beat comparisons drawn from all 450 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering CDC. Shared-story counts are live from our verified record — not editorial picks.
A cluster of three infant botulism cases, despite zero positive C. botulinum tests in product lots, has forced Nara Organics to recall all whole milk powdered formula. The incident raises critical quality control and sterility challenges for the organic infant nutrition sector.
A federal judge has issued a temporary injunction against Robert F. Kennedy Jr.’s proposed changes to national vaccine policy, citing potential risks to public health. The ruling provides a reprieve for pharmaceutical manufacturers and public health agencies while the legal merits of the administration's agenda are debated.
Preliminary reports from US health officials indicate that this season's influenza vaccines provided lower-than-expected protection against circulating strains. The findings underscore the persistent challenge of viral mismatch and are expected to accelerate the industry's shift toward next-generation mRNA and recombinant vaccine technologies.
The CDC has issued urgent travel advisories for several popular tourist destinations following a confirmed spread of poliovirus. This development signals a significant setback for global eradication efforts and is expected to drive a surge in demand for inactivated poliovirus vaccines (IPV).
A growing trend of retaining and consuming human tissue, such as placentas and surgical remains, is raising significant biohazard and infection concerns. Medical experts warn that the lack of regulatory oversight and clinical evidence for these practices poses serious risks to public health.
The United States and the Democratic Republic of the Congo have finalized a $1.2 billion health partnership aimed at strengthening healthcare infrastructure and disease surveillance. This multi-year commitment focuses on global health security, infectious disease control, and improving maternal and child health outcomes.
California and 14 other states have filed a federal lawsuit against the Trump administration, challenging recent modifications to the recommended childhood immunization schedule. The coalition argues that these changes lack scientific justification and threaten to undermine decades of public health progress.
A coalition of over a dozen states, led by Arizona, has filed a federal lawsuit against the Trump administration to block the rollback of childhood vaccine recommendations. The plaintiffs argue that the changes to CDC guidelines bypass scientific protocols and present an immediate threat to national public health safety.
NIH Director Dr. Jay Bhattacharya has been appointed as the acting head of the CDC, creating a historic dual-leadership role over the two most powerful U.S. health agencies. This consolidation marks a significant shift in public health strategy, placing research and implementation under a single executive.
CDC is linked from 9 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.